Positive results were announced from the phase 3 STOP-301 study evaluating INP104 (intranasal dihydroergotamine mesylate; Impel NeuroPharma) for the treatment of acute migraine in adults.
The investigators observed greater brain activations in the frontal regions associated with cognitive regulation of pain after CBT.
Migraine attacks were more frequent in post-pubertal compared to pre-pubertal girls, with no observed difference in headache characteristics between the groups.
Compared with medical therapy alone, yoga plus medical care is better for the treatment of episodic migraines.
Researchers evaluated sensory function in the trigeminocervical region in patients with cluster headache, migraine headache, and tension-type headache.
Repetitive multiple cranial nerve blocks may offer a clinically meaningful benefit as a preventative measure in patients with chronic migraine.
Youth with a history of status migranosus are more likely to experience an increase of >4 headache days per month during a follow-up evaluation.
Treatment with fremanezumab for episodic and chronic migraine was found to have a favorable cardiovascular safety profile in patients with and without a history of cardiovascular disease.
Study findings suggest that pain modulation may be impaired in patients with migraine in the headache-free interval, despite an unaffected sensory profile.
Biohaven announced that rimegepant is now available for the acute treatment of migraine with or without aura in adults.
